Ipca Laboratories Ltd is trading at ₹1,575.6, down 0.47% on the day as of 13:19 IST on the NSE, according to reports from Business Standard. The stock has now declined for a fifth consecutive session, continuing its downward momentum in the current trading session.
The pharmaceutical company's stock has experienced significant underperformance over the past year, declining 15.63% compared to a 4.2% slide in the NIFTY and a 9.97% fall in the Nifty Pharma index, as reported by Business Standard. This performance gap highlights Ipca Laboratories' relative weakness against broader market indices.
The broader market showed positive momentum with the benchmark NIFTY up around 1.17% to 23,899.05 and the Sensex at 76,440.61, up 1.21%, according to Business Standard. However, Ipca Laboratories continued its decline despite the positive market sentiment, indicating company-specific factors may be driving the stock's performance.
Over the past month, Ipca Laboratories has declined approximately 4.29%, while the Nifty Pharma index has eased around 2.12% and is currently quoting at 24,380.05, down 0.58% on the day, as reported by Business Standard. The stock's trading volume stood at 77,999 shares today, compared to the daily average of 3.04 lakh shares in the last one month.
The stock's price-to-earnings ratio stands at 34.84 based on trailing twelve months earnings ending March 2026, according to Business Standard. This valuation metric provides context for the stock's current trading levels and relative performance against other pharmaceutical companies in the sector.
